EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Anti‐Carbamylated Protein Antibodies Stabilize Carbamylated Histone H3 to Promote Synovial Activation and Neutrophil Extracellular Trap‐Mediated Bone Loss in Rheumatoid Arthritis

Shuichiro Nakabo iD, Norio Hanata, Eduardo Patino-Martinez, Ronald Holewinski, Ana Barrera-Vargas, Javier Merayo-Chalico, Scott A Coonrod, David A Fox iD, Mariana J Kaplan, Carmelo Carmona-Rivera iD

Arthritis & Rheumatology · 2026

DOI: 10.1002/art.70158 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Shuichiro Nakabo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Marylan…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Histones, Protein Carbamylation, Extracellular Traps. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Intramural NIH HHS, Japan Society for the Promotion of Science, NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Carbamylation, a nonenzymatic post‐translational modification, contributes to rheumatoid arthritis (RA) pathogenesis. Anti‐carbamylated protein antibodies (anti‐CarP) occur in around 50% of patients with RA and associate with greater joint damage. Neutrophil extracellular traps (NETs) are a major source of carbamylated autoantigens. We sought to study how carbamylation and anti‐CarP antibodies promote joint pathology.

Methods

NETs were generated with calcium ionophore and analyzed for carbamylation by immunofluorescence, flow cytometry, and mass spectrometry. Enzymatic pathways were interrogated using pharmacologic inhibitors and peptidyl arginine deiminase (PAD)2/4 deficient mice. Degradation kinetics of carbamylated histone H3 (carH3) were evaluated with neutrophil elastase (NE) and anti‐CarP IgG from patients with RA. Toll‐like receptor 4 (TLR4) activation was quantified using a HEK293 reporter line. RA fibroblast‐like synoviocytes (FLS) were stimulated with carH3 or carH3‐IgG immune complexes (ICs) and profiled by RNA‐sequencing and enzyme‐linked immunosorbent assay.

Results

Histone carbamylation, especially of H3, occurred during NETosis and was independent of peptidylarginine deiminase‐4, myeloperoxidase, NE, or oxidative pathways. CarH3 was rapidly degraded by NE, but anti‐CarP antibodies protected it from proteolysis. NETs exposed to anti‐CarP IgG triggered stronger TLR4 activation and enhanced osteoclastogenesis. In FLS, carH3 and particularly carH3‐ICs induced robust up‐regulation of pro‐inflammatory genes and cytokine secretion (interleukin [IL‐]6, IL‐8, MCP‐1, GM‐CSF). Transcriptomic analysis revealed enrichment of immune activation, chemotaxis, and angiogenesis pathways, most pronounced with carH3‐IC.

Conclusion

Anti‐CarP antibodies stabilize carH3 within NETs, amplifying its pro‐inflammatory and osteoclastogenic activity. The resulting carH3‐IgG ICs potently activate FLS, linking humoral immunity to tissue inflammation and bone destruction in RA. These findings identify carH3 stabilization as a potential therapeutic target in antibody‐mediated joint damage. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidHistonesProtein CarbamylationExtracellular TrapsAutoantibodiesSynovial MembraneHumansAnimalsProtein-Arginine Deiminase Type 4MiceProtein-Arginine Deiminase Type 2SynoviocytesToll-Like Receptor 4FemaleHEK293 CellsImmunoglobulin GLeukocyte Elastase

Substanzen

HistonesProtein-Arginine Deiminase Type 4AutoantibodiesProtein-Arginine Deiminase Type 2peptidylarginine deiminase 4, mousePADI4 protein, humanToll-Like Receptor 4PADI2 protein, humanImmunoglobulin GLeukocyte Elastase

Autor:innen und Institutionen

  • Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland.
  • Frederick National Laboratory for Cancer Research, National Institutes of Health, Bethesda, Maryland.
  • Department of Medical Education, Instituto Nacional de Ciencias Médicas y de la Nutrición, Salvador Zubirán, Mexico City, Mexico.
  • Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y de la Nutrición, Salvador Zubirán, Mexico City, Mexico.
  • Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, New York.
  • Division of Rheumatology and Clinical Autoimmunity Center of Excellence, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.

ORCID-Profile: Shuichiro Nakabo, David A Fox, Carmelo Carmona-Rivera

Förderung

  • Intramural NIH HHS
  • Japan Society for the Promotion of Science
  • NIAMS NIH HHS
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases

Zitieren

APA

Nakabo, S., Hanata, N., Patino-Martinez, E., Holewinski, R., Barrera-Vargas, A., Merayo-Chalico, J., Coonrod, S. A., Fox, D. A., Kaplan, M. J., & Carmona-Rivera, C. (2026). Anti‐Carbamylated Protein Antibodies Stabilize Carbamylated Histone H3 to Promote Synovial Activation and Neutrophil Extracellular Trap‐Mediated Bone Loss in Rheumatoid Arthritis. Arthritis & Rheumatology. https://doi.org/10.1002/art.70158

Vancouver

Nakabo S, Hanata N, Patino-Martinez E, Holewinski R, Barrera-Vargas A, Merayo-Chalico J, et al. Anti‐Carbamylated Protein Antibodies Stabilize Carbamylated Histone H3 to Promote Synovial Activation and Neutrophil Extracellular Trap‐Mediated Bone Loss in Rheumatoid Arthritis. Arthritis & Rheumatology. 2026. doi:10.1002/art.70158

BibTeX
@article{Nakabo2026,
  author = {Nakabo, Shuichiro and Hanata, Norio and Patino-Martinez, Eduardo and Holewinski, Ronald and Barrera-Vargas, Ana and Merayo-Chalico, Javier and Coonrod, Scott A and Fox, David A and Kaplan, Mariana J and Carmona-Rivera, Carmelo},
  title = {Anti‐Carbamylated Protein Antibodies Stabilize Carbamylated Histone H3 to Promote Synovial Activation and Neutrophil Extracellular Trap‐Mediated Bone Loss in Rheumatoid Arthritis},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  doi = {10.1002/art.70158}
}
Kostenlos starten →